Bioinformatics Intern
ZoetisFull Time
Entry Level & New Grad
Winter Garden, Florida, United States
Key technologies and capabilities for this role
Common questions about this position
The intern will apply predictive modeling to identify biomarkers for STK11 or KEAP1 genetic variations, utilize spatial transcriptomic data to characterize molecular features in NSCLC, and work on flexible deliverables tailored to their interests and skills.
Candidates must be currently enrolled in a PhD program in bioinformatics, computational biology, biostatistics, or a related quantitative field, with proficiency in at least one scripting language (R preferred), familiarity with data reproducibility best practices, and experience analyzing spatial transcriptomics data and/or building prediction models using omics data.
The full-time internship will take place from June to August 2026.
The environment is challenging, meaningful, and life-changing, with uniquely interesting work, opportunities to grow alongside high-achieving teams in a collaborative, cross-functional team in a dynamic R&D setting, and a focus on balance and flexibility.
Strong candidates are PhD students in relevant quantitative fields with hands-on experience in spatial transcriptomics or omics prediction models, proficiency in R or scripting, data reproducibility practices like Git, plus a foundation in cancer biology, excellent communication skills, and US work authorization.
Develops and delivers biopharmaceutical medicines
Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.